Atlas Trials

Novartis Pharmaceuticals

2,690 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Novartis Pharmaceuticals

RecordFirmDate
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta (NCT00131118)Novartis Pharmaceuticals2004-07-01
Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). (NCT01090323)Novartis Pharmaceuticals2004-07-01
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) (NCT00171977)Novartis Pharmaceuticals2004-07-01
A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis. (NCT00154336)Novartis Pharmaceuticals2004-07-01
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis (NCT00171639)Novartis Pharmaceuticals2004-06-01
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF) (NCT00154232)Novartis Pharmaceuticals2004-06-01
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (NCT00117767)Novartis Pharmaceuticals2004-06-01
Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels (NCT00154193)Novartis Pharmaceuticals2004-06-01
Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS) (NCT00150007)Novartis Pharmaceuticals2004-06-01
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate (NCT00100555)Novartis Pharmaceuticals2004-06-01
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis (NCT00100620)Novartis Pharmaceuticals2004-06-01
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid (NCT00097812)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes (NCT00099944)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients (NCT00239863)Novartis Pharmaceuticals2004-05-01
Verification Study of Ciclosporin for Atopic Dermatitis (NCT00232076)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes (NCT00099853)Novartis Pharmaceuticals2004-05-01
Long-term Study of Ciclosporin for Atopic Dermatitis (NCT00232063)Novartis Pharmaceuticals2004-05-01
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia (NCT00084071)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes (NCT00099931)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes (NCT00099918)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes (NCT00099892)Novartis Pharmaceuticals2004-05-01
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01197287)Novartis Pharmaceuticals2004-05-01
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation (NCT00098735)Novartis Pharmaceuticals2004-04-01
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease (NCT00088608)Novartis Pharmaceuticals2004-04-01
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men (NCT00097825)Novartis Pharmaceuticals2004-04-01
Non-small Cell Lung Cancer Study US75 (Z-PACT) (NCT00086268)Novartis Pharmaceuticals2004-04-01
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma (NCT00079937)Novartis Pharmaceuticals2004-04-01
MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive (NCT00284921)Novartis Pharmaceuticals2004-04-01
A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes (NCT00099905)Novartis Pharmaceuticals2004-04-01
Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (NCT00239811)Novartis Pharmaceuticals2004-04-01
Pediatric Hypothalamic Obesity (NCT00076362)Novartis Pharmaceuticals2004-03-01
Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events (NCT00346242)Novartis Pharmaceuticals2004-03-01
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients (NCT00088582)Novartis Pharmaceuticals2004-03-01
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer (NCT00171314)Novartis Pharmaceuticals2004-03-01
Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11% (NCT00101673)Novartis Pharmaceuticals2004-03-01
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment (NCT00237198)Novartis Pharmaceuticals2004-03-01
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients (NCT00303329)Novartis Pharmaceuticals2004-03-01
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00093600)Novartis Pharmaceuticals2004-02-01
Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis (NCT00100607)Novartis Pharmaceuticals2004-02-01
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors (NCT00088595)Novartis Pharmaceuticals2004-01-01
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril (NCT00171119)Novartis Pharmaceuticals2004-01-01
Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes (NCT00099866)Novartis Pharmaceuticals2004-01-01
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) (NCT00116376)Novartis Pharmaceuticals2004-01-01
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates (NCT00172016)Novartis Pharmaceuticals2004-01-01
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer (NCT00073528)Novartis Pharmaceuticals2003-12-09
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy (NCT00087659)Novartis Pharmaceuticals2003-12-01
Safety of CHIR-258 (TKI258) in Advanced Solid Tumors (NCT01270906)Novartis Pharmaceuticals2003-12-01
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis (NCT00076336)Novartis Pharmaceuticals2003-12-01
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (NCT00099242)Novartis Pharmaceuticals2003-11-01
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant (NCT00099749)Novartis Pharmaceuticals2003-11-01
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy (NCT00237146)Novartis Pharmaceuticals2003-11-01
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients (NCT00170833)Novartis Pharmaceuticals2003-11-01
Dose-Escalation Study in Advanced Colon Cancer Patients (NCT00969046)Novartis Pharmaceuticals2003-11-01
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification (NCT00124709)Novartis Pharmaceuticals2003-10-01
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (NCT00081926)Novartis Pharmaceuticals2003-10-01
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme (NCT00107237)Novartis Pharmaceuticals2003-10-01
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia (NCT00154349)Novartis Pharmaceuticals2003-10-01
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis (NCT00241111)Novartis Pharmaceuticals2003-09-01
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT00072709)Novartis Pharmaceuticals2003-09-01
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. (NCT00390858)Novartis Pharmaceuticals2003-09-01
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer (NCT00219271)Novartis Pharmaceuticals2003-09-01
A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes (NCT00099957)Novartis Pharmaceuticals2003-09-01
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer (NCT00171834)Novartis Pharmaceuticals2003-08-01
Study of Oral AEE788 in Adults With Advanced Cancer (NCT00118456)Novartis Pharmaceuticals2003-07-01
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy (NCT01316458)Novartis Pharmaceuticals2003-06-01
Bisphosphonate Treatment of Osteogenesis Imperfecta (NCT00063479)Novartis Pharmaceuticals2003-06-01
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity (NCT01044186)Novartis Pharmaceuticals2003-06-01
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant (NCT00099736)Novartis Pharmaceuticals2003-05-07
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions (NCT00067080)Novartis Pharmaceuticals2003-05-01
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias (NCT00061763)Novartis Pharmaceuticals2003-05-01
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions (NCT00061750)Novartis Pharmaceuticals2003-05-01
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion (NCT00238472)Novartis Pharmaceuticals2003-05-01
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. (NCT00171340)Novartis Pharmaceuticals2003-05-01
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (NCT00239785)Novartis Pharmaceuticals2003-04-01
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients (NCT00238446)Novartis Pharmaceuticals2003-04-01
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (NCT00063609)Novartis Pharmaceuticals2003-04-01
Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women (NCT00237133)Novartis Pharmaceuticals2003-03-01
Freedom Study: Myfortic in Kidney Transplant Patients (NCT00101738)Novartis Pharmaceuticals2003-03-01
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer (NCT00171847)Novartis Pharmaceuticals2003-03-01
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies (NCT00621244)Novartis Pharmaceuticals2003-03-01
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas (NCT00242541)Novartis Pharmaceuticals2003-03-01
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 (NCT00052013)Novartis Pharmaceuticals2003-02-01
Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study (NCT01033747)Novartis Pharmaceuticals2003-02-01
Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole (NCT00237224)Novartis Pharmaceuticals2003-02-01
A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) (NCT00238979)Novartis Pharmaceuticals2003-01-01
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer (NCT00056446)Novartis Pharmaceuticals2003-01-01
An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients (NCT00239044)Novartis Pharmaceuticals2002-12-01
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients. (NCT00238992)Novartis Pharmaceuticals2002-12-01
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients (NCT00149994)Novartis Pharmaceuticals2002-12-01
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea (NCT00050635)Novartis Pharmaceuticals2002-12-01
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors (NCT01275222)Novartis Pharmaceuticals2002-11-13
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly (NCT00225979)Novartis Pharmaceuticals2002-11-01
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases (NCT00242554)Novartis Pharmaceuticals2002-10-01
Letrozole in the Treatment of Severe and Recurrent Endometriosis (NCT00240942)Novartis Pharmaceuticals2002-10-01
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis (NCT00237159)Novartis Pharmaceuticals2002-10-01
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) (NCT00237172)Novartis Pharmaceuticals2002-09-01
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy (NCT00050011)Novartis Pharmaceuticals2002-09-01
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome (NCT00171860)Novartis Pharmaceuticals2002-09-01
EPO906 in Carcinoid and Other Neuroendocrine Tumors (NCT00050349)Novartis Pharmaceuticals2002-07-01
Pediatric Epilepsy Study (NCT00050947)Novartis Pharmaceuticals2002-07-01
← Previous Next →

Track Novartis Pharmaceuticals automatically

Every clearance here is in the API, with alerts when new ones post.